309 related articles for article (PubMed ID: 11134203)
1. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
2. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
3. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
Mac Manus MP; Hicks RJ; Ball DL; Kalff V; Matthews JP; Salminen E; Khaw P; Wirth A; Rischin D; McKenzie A
Cancer; 2001 Aug; 92(4):886-95. PubMed ID: 11550162
[TBL] [Abstract][Full Text] [Related]
4. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
Gregory DL; Hicks RJ; Hogg A; Binns DS; Shum PL; Milner A; Link E; Ball DL; Mac Manus MP
J Nucl Med; 2012 Jul; 53(7):1007-15. PubMed ID: 22677701
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
6. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
7. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
Kolodziejczyk M; Kepka L; Dziuk M; Zawadzka A; Szalus N; Gizewska A; Bujko K
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1008-14. PubMed ID: 20656419
[TBL] [Abstract][Full Text] [Related]
8. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
[TBL] [Abstract][Full Text] [Related]
9. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
[TBL] [Abstract][Full Text] [Related]
10. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
[TBL] [Abstract][Full Text] [Related]
11. Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy.
MacManus MP; Hicks RJ; Ball DL; Ciavarella F; Binns D; Hogg A; Kalff V; Ware R; Wirth A; Salminen E; McKenzie A
Australas Radiol; 2001 Nov; 45(4):483-90. PubMed ID: 11903182
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
13. Is there any improvement in clinical staging with
Gedik GK; Yilmaz F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):348-354. PubMed ID: 31378538
[TBL] [Abstract][Full Text] [Related]
14. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
[TBL] [Abstract][Full Text] [Related]
15. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J; Grutters J; Wanders R; Boersma L; Oellers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Fatah SA; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2009 Mar; 45(4):588-95. PubMed ID: 19046631
[TBL] [Abstract][Full Text] [Related]
16. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
17. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
18. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
20. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]